TMDX - TransMedics Group Inc Stock Price, Fair Value and News

$166.00+10.04 (+6.44%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

TMDX RSI Chart

TMDX Valuation

Market Cap

5.2B

Price/Earnings (Trailing)

1.7K

Price/Sales (Trailing)

14.5

EV/EBITDA

174.57

Price/Free Cashflow

-26.85

TMDX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

TMDX Fundamentals

TMDX Revenue

Revenue (TTM)

358.8M

Rev. Growth (Yr)

117.87%

Rev. Growth (Qtr)

18.02%

TMDX Earnings

Earnings (TTM)

3.0M

Earnings Growth (Yr)

1.3K%

Earnings Growth (Qtr)

-0.02%

TMDX Price Action

Last 7 days

8.5%

Last 30 days

-6.6%

Last 90 days

8.3%

Trailing 12 Months

166.6%

TMDX Profitability

Operating Margin

60.71%

EBT Margin

0.41%

Return on Equity

1.58%

Return on Assets

0.4%

Free Cashflow Yield

-3.72%

TMDX Financial Health

Current Ratio

9.37

Debt/Equity

2.36

Debt/Cashflow

0.05

TMDX Investor Care

Shares Dilution (1Y)

2.23%

Diluted EPS (TTM)

0.04

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	296.9M	358.8M	0	0
2023	119.1M	151.1M	191.8M	241.6M
2022	39.1M	51.4M	71.8M	93.5M
2021	25.2M	29.9M	28.2M	30.3M
2020	26.5M	24.2M	24.1M	25.6M
2019	15.2M	17.9M	21.1M	23.6M
2018	0	0	0	13.0M

Get all data in R, Python etc through our Historical Stock Data APIs

About TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

CEO	Dr. Waleed H. Hassanein M.D.
WEBSITE	transmedics.com
SECTOR	Healthcare
INDUSTRY	Medical Devices
EMPLOYEES	212

TransMedics Group Inc Frequently Asked Questions

What is the ticker symbol for TransMedics Group Inc? What does TMDX stand for in stocks?

TMDX is the stock ticker symbol of TransMedics Group Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of TransMedics Group Inc (TMDX)?

As of Wed Sep 18 2024, market cap of TransMedics Group Inc is 5.2 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TMDX stock?

You can check TMDX's fair value in chart for subscribers.

Is TransMedics Group Inc a good stock to buy?

The fair value guage provides a quick view whether TMDX is over valued or under valued. Whether TransMedics Group Inc is cheap or expensive depends on the assumptions which impact TransMedics Group Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TMDX.

What is TransMedics Group Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Sep 18 2024, TMDX's PE ratio (Price to Earnings) is 1.73 Thousand and Price to Sales (PS) ratio is 14.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TMDX PE ratio will change depending on the future growth rate expectations of investors.